Published in Oncotarget on December 22, 2015
Heat*seq: an interactive web tool for high-throughput sequencing experiment comparison with public data. Bioinformatics (2016) 0.77
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. Sci Rep (2017) 0.75
SHARPIN Facilitates p53 Degradation in Breast Cancer Cells. Neoplasia (2017) 0.75
Cross-talk between p21-activated kinase 4 and ERα signaling triggers endometrial cancer cell proliferation. Oncotarget (2017) 0.75
DNA Methylation of a Novel PAK4 Locus Influences Ototoxicity Susceptibility following Cisplatin and Radiation Therapy for Pediatric Embryonal Tumors. Neuro Oncol (2017) 0.75
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Breast cancer statistics, 2013. CA Cancer J Clin (2013) 7.35
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med (2011) 4.32
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res (2014) 2.66
Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev (2001) 2.54
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics (2011) 2.09
Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell (2004) 2.08
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem (2001) 2.07
The p21Rac/Cdc42-activated kinases (PAKs). Int J Biochem Cell Biol (1998) 2.00
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A (2010) 1.94
Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem (2001) 1.93
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem (2001) 1.78
Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol (2001) 1.76
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol (2002) 1.60
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A (2010) 1.50
The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res (2008) 1.48
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene (2007) 1.43
Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol (2005) 1.42
A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal (2008) 1.38
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci (2002) 1.24
PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J (2007) 1.19
Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res (1984) 1.17
P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. J Cell Biol (2002) 1.17
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
P21 activated kinases: structure, regulation, and functions. Small GTPases (2014) 1.06
Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res (2010) 1.05
LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett (2011) 1.04
A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer (2011) 1.02
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun (2013) 0.99
PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat (2010) 0.99
P21-activated kinase 4--not just one of the PAK. Eur J Cell Biol (2013) 0.99
p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration. J Biol Chem (2010) 0.98
Integrin-mediated cell attachment induces a PAK4-dependent feedback loop regulating cell adhesion through modified integrin alpha v beta 5 clustering and turnover. Mol Biol Cell (2010) 0.98
Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol (1994) 0.95
AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer. Oncotarget (2015) 0.93
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res (2015) 0.93
Auto-regulation of the estrogen receptor promoter. J Steroid Biochem Mol Biol (1997) 0.92
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. J Med Chem (2014) 0.90
PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance. Oncogene (2012) 0.89
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene (2014) 0.86
Signaling, Regulation, and Specificity of the Type II p21-activated Kinases. J Biol Chem (2015) 0.84
Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) (2012) 0.81
RING finger protein 31 promotes p53 degradation in breast cancer cells. Oncogene (2015) 0.80
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget (2014) 0.80
Tamoxifen: too much of a good thing? J Clin Oncol (1999) 0.79
Liver X receptor in cholesterol metabolism. J Endocrinol (2009) 1.59
AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer. Oncotarget (2015) 0.93
Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism. Cancer Res (2016) 0.78